Phytocannabinoids as novel therapeutic agents in CNS disorders

Area of Science:

• Pharmacology
• Neuroscience
• Cannabinoid Research

Background:

• Cannabis sativa contains over 100 phytocannabinoids (pCBs), with Δ(9)-tetrahydrocannabinol (Δ(9)-THC) being the primary psychoactive compound.
• The endogenous cannabinoid system (ECS) is activated by Δ(9)-THC, mediating its effects, but its psychoactivity limits therapeutic use.
• Research is expanding to non-Δ(9)-THC phytocannabinoids like cannabidiol (CBD) and cannabigerol (CBG) for potential therapeutic applications.

Purpose of the Study:

• To review the effects of various phytocannabinoids (pCBs) in preclinical models of central nervous system (CNS) diseases.
• To examine available clinical trial data supporting the therapeutic effects of non-Δ(9)-THC pCBs.
• To highlight the potential of novel pCBs as future therapeutic agents.

Main Methods:

• Literature review of preclinical studies on pCB effects in CNS disease models.
• Analysis of clinical trial data for therapeutic efficacy of pCBs.
• Exploration of the pharmacological targets of non-Δ(9)-THC pCBs beyond CB receptors.

Main Results:

• Several non-Δ(9)-THC pCBs, including CBD, CBG, Δ(9)-THCV, and CBDV, demonstrate therapeutic potential in preclinical CNS disease models.
• These pCBs interact with a diverse range of pharmacological targets, not exclusively CB receptors.
• Emerging data suggests potential applications in epilepsy, neurodegenerative diseases, affective disorders, and feeding behavior modulation.

Conclusions:

• Phytocannabinoids beyond Δ(9)-THC offer promising therapeutic avenues for CNS disorders.
• These compounds act through various mechanisms, expanding their potential clinical utility.
• The development of non-Δ(9)-THC pCB-based medicines is anticipated in the near future.